Vir Biotechnology (VIR) Current Deferred Revenue (2018 - 2025)

Vir Biotechnology has disclosed Current Deferred Revenue across 8 years of filings, most recently posting $10.1 million for Q2 2025.

• Current Deferred Revenue for Q2 2025 came in at $10.1 million, down 39.47% year-over-year; the trailing twelve-month figure through Jun 2025 was $10.1 million (down 39.47% YoY), and the FY2024 annual result was $12.6 million, down 80.5% from the prior year.
• Current Deferred Revenue came in at $10.1 million for Q2 2025 at Vir Biotechnology, down from $11.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $262.9 million in Q1 2021 to a low of $10.1 million in Q2 2025.
• The 5-year median for Current Deferred Revenue is $16.2 million (2023), against an average of $48.0 million.
• Across the five-year window, Current Deferred Revenue surged 5148.08% in 2021 and sank 94.1% in 2022, its largest moves.
• Vir Biotechnology's Current Deferred Revenue stood at $98.2 million in 2021, then sank by 84.2% to $15.5 million in 2022, then jumped by 317.95% to $64.9 million in 2023, then sank by 80.5% to $12.6 million in 2024, then declined by 20.07% to $10.1 million in 2025.
• The last three Current Deferred Revenue figures came in at $10.1 million (Q2 2025), $11.9 million (Q1 2025), and $12.6 million (Q4 2024), per Business Quant data.